GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Cyclically Adjusted Price-to-FCF

Kintara Therapeutics (STU:3DMA) Cyclically Adjusted Price-to-FCF : (As of Oct. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kintara Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Kintara Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Cyclically Adjusted Price-to-FCF Chart

Kintara Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Kintara Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Kintara Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Kintara Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Kintara Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.024/132.5538*132.5538
=-0.024

Current CPI (Jun. 2024) = 132.5538.

Kintara Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -41.889 100.428 -55.289
201412 -46.684 99.070 -62.463
201503 -47.632 99.621 -63.378
201506 -36.050 100.684 -47.461
201509 -59.476 100.392 -78.530
201512 -51.455 99.792 -68.347
201603 -39.045 100.470 -51.513
201606 -62.864 101.688 -81.945
201609 -62.478 101.861 -81.304
201612 -59.739 101.863 -77.738
201703 -61.304 102.862 -79.000
201706 -109.643 103.349 -140.626
201709 -64.226 104.136 -81.753
201712 -40.044 104.011 -51.033
201803 -49.587 105.290 -62.427
201806 -47.130 106.317 -58.761
201809 -38.848 106.507 -48.349
201812 -17.667 105.998 -22.093
201903 -25.940 107.251 -32.060
201906 -27.203 108.070 -33.366
201909 -13.629 108.329 -16.677
201912 -6.754 108.420 -8.257
202003 -5.452 108.902 -6.636
202006 -9.996 108.767 -12.182
202009 -10.202 109.815 -12.314
202012 -8.982 109.897 -10.834
202103 -6.648 111.754 -7.885
202106 -5.997 114.631 -6.935
202109 -6.286 115.734 -7.200
202112 -4.652 117.630 -5.242
202203 -4.824 121.301 -5.272
202206 -3.751 125.017 -3.977
202209 -4.554 125.227 -4.820
202212 -1.242 125.222 -1.315
202303 -1.015 127.348 -1.056
202306 -0.823 128.729 -0.847
202309 -0.718 129.860 -0.733
202312 -0.448 129.419 -0.459
202403 -0.047 131.776 -0.047
202406 -0.024 132.554 -0.024

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kintara Therapeutics  (STU:3DMA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Kintara Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines